Effects of a human compact anti-ErbB2 antibody on gastric cancer

Gastric Cancer

Volumn 17, Issue 1, 2014, Pages 107-115

  Fedele, Carmine ^a   Carvalho, Silvia ^b,c,d   Riccio, Gennaro ^a   Paciello, Rolando ^a   Laccetti, Paolo ^a   Schmitt, Fernando ^b,c   De Lorenzo, Claudia ^a,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

ErbB2 Her2; Gastric cancer; Immunotherapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 HUMAN COMPACT ANTIBODY; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; STOMACH CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891630582     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0244-z     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33(4):315-24.
3. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009;10(9):903-12.
4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-55.
5. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer. 2001;2(2):129-35. discussion 36-37.
6. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986;6(3):955-8.
7. Semba K, Kamata N, Toyoshima K, Yamamoto TA. v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA. 1985;82(19):6497-501.
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
9. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9.
10. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II-alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273-8.
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
12. Stebbing J, Copson E, O'Reilly S. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev. 2000;26(4):287-90.
13. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(6):795-805.
14. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008;32(1):89-95.
15. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol. 2005;27(3):681-5.
16. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
17. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11):1949-59.
18. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269-80.
19. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, et al. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer. 2004;91(6):1200-4.
20. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002;8(6):1710-9.
21. De Lorenzo C, D'Alessio G. Human anti-ErbB2 immunoagents: immunoRNases and compact antibodies. FEBS J. 2009;276(6):1527-35.
22. Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 2000;27(6 suppl 11):9-14 (discussion 92-100).
23. Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. 2012;133(2):511-21.
24. Fedele C, Riccio G, Malara AE, D'Alessio G, De Lorenzo C. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat. 2012;134(2):595-602.
25. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J. 2009;23(9):3171-8.
26. Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, et al. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer. 2010;102(3):513-9.
27. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010;36(suppl 3):S11-S15.
28. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G. Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis (Oxf). 2005;26:1890-5.
29. Troise F, Cafaro V, Giancola C, D'Alessio G, De Lorenzo C. Differential binding of human immunoagents and herceptin to the ErbB2 receptor. FEBS J. 2008;275(20):4967-79.
30. Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, et al. A novel ErbB2 epitope targeted by human antitumor immunoagents. FEBS J. 2011;278(7):1156-66.
31. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27(34):5838-47.
32. De Lorenzo C, Troise F, Cafaro V, D'Alessio G. Combinatorial experimental protocols for erbicin-derived immunoagents and herceptin. Br J Cancer. 2007;97:1354-60.